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AntihypertensiveAbstract Objectives: Observational study to assess essential hypertension patient’s compliance on
Irbesartan, rationale for prescribing Irbesartan, proﬁle of patient for whom it is prescribed, and
assess patient/physician satisfaction.
Methods: Naı¨ve/uncontrolled patients with essential hypertension; for whom physicians decide to
prescribe Irbesartan-based-regimen are followed up for 4 months to assess compliance, tolerability,
satisfaction, and identify reasons for prescription. Physicians were required to ﬁll a case-report-
form and a simple questionnaire to identify patients’ characteristics, give reason(s) for prescription,
and persistence/non-persistence of patients/physicians. Satisfaction, safety proﬁle, and blood pres-
sure control were also assessed.
Results: Total of 62.1% (n= 3971) of all screened patients (n= 6399, Naı¨ve = 31.04%, uncon-
trolled = 68.96%) were prescribed an Irbesartan based regimen. Efﬁcacy, safety, and cost; in
that ranking order, were the main reasons for prescribing speciﬁc antihypertensive agent. By
the end of the study, satisfaction for Irbesartan 150 mg, 300 mg, and 300 mg/12.5 mg was
95.6%, 96.8%, and 96.5%, respectively; up from 72.6% general patient satisfaction with their
current regimen at screening visit. Physicians showed a similar improvement in satisfaction to
96.4%, 97.1%, and 95.8, respectively, up from 27.3% satisfaction with previous regimen.
Patient’s compliance increased up from 86% at the beginning of the study to a mean of
96.2% by the end of the study.
36Conclusion: A total of 96%± 0.8 of Irbesartan population were satisﬁed with their Irbesartan reg-imen. Reasons for prescribing a speciﬁc antihypertensive class were identiﬁed as efﬁcacy, safety, and
cost. Angiotensin-Receptor-Blockers were the antihypertensive of choice for 68.9% of physicians
due to its efﬁcacy (96.5%) and safety (85.9%). The majority (91.49%) of side effects were recorded
as being ‘mild’, no serious adverse events were recorded.
ª 2012 Egyptian Society of Cardiology. Production and hosting by Elsevier B.V. All rights reserved.
K. Leon et al.1. Introduction
Hypertension is one of the major cardiovascular diseases
worldwide; in 2000; 26% of the adult population had hyper-
tension.1 It has been estimated that hypertension is responsible
for 4% of the global burden of disease.2 It is one of the major
causes of morbidity and mortality in both developing and
developed regions, particularly cardiovascular and renal dis-
eases.3 Hypertensive heart disease, is the largest single contrib-
utor among the remaining causes of cardiovascular disease
(CVD) morbidity & mortality,4 accounting for as much as
11% in the Middle East. And, out of the 17 countries of the
middle East & North Africa (MENA) region, which represents
6% (306 million people), of the whole world’s population,
Egypt alone is the most populous country of the region , hav-
ing 24% of the total inhabitants of the region.5
According to the National Health and Nutrition Examina-
tion Surveys (NHANES) III study in the United States, less
than a quarter of hypertensive patients have their blood pres-
sure (BP) in good control (under 140/90 mmHg).6 Hyperten-
sion is also a major health problem affecting more than 20%
of the Canadian population.7 It has been estimated that in
Canada, only 16% of hypertensive patients are controlled,
23% are treated but not controlled, 19% are not treated and
42% are unaware of their condition.8 In Egypt, a National
Hypertension Project implemented in the 90s showed that
Hypertension is affecting more than 26% of population above
25 years, only 8% of hypertensive patients are controlled, 16%
are treated but not controlled, 14% are not treated with med-
ications and 63% are unaware of their condition.9
One of themajor factors in this poor control is the lack of pa-
tient adherence to treatment.10 Overall hypertensive patients are
estimated to take only 53–70% of the medication prescribed for
them.11–13 Furthermore, noncompliance, has been reported to
be one of the main causes for refractory hypertension.14
In 1999 the total cost of treating hypertension in the United
States (US) was estimated to be $33.3 billion, including $8.8
billion for lost productivity resulting from hypertension-
related morbidity and mortality.9
Numerous studies have examined treatment persistence in
hypertension. Some of these predated the introduction of newer
drug classes.15–20 Most guidelines suggest that initial combina-
tion treatment should include a thiazide diuretic and either an
angiotensin receptor blocker (ARB), an angiotensin-converting
enzyme inhibitor (ACE-I), a calcium channel blocker (CCB), or
a beta-blocker.6,21 Actually Sever PS andMesserli FH,22 in their
latest article review, published in Oct 2011, in the European
Heart Journal, under the title of Hypertension management
2011: optimal combination therapy, they enlist, ARB + diuret-
ics combination as the PREFERED one, as the activation of
RAAS system due to intravascular volume depletion by diuret-
ics, is mitigated by the addition of RAAS blocker.21 In addition,for patients with chronic renal disease or type 2 diabetes, combi-
nations including an ARB or ACE-I are recommended23 how-
ever, with caution due to the possible combined hyperkalemic
effect of both agents, in this particular subset of patients. The
usefulness of ﬁxed dose (FD) ARB/hydrochlorothiazide
(HCTZ) combinations in effectively treating hypertension,
including difﬁcult-to-treat and severely hypertensive patients,
has been demonstrated for several different ARBs.16,24 Promis-
ing results have also been reported for FD combinations regard-
ing improvements in clinical endpoints, as well as achieving BP
targets. In addition, combining HCTZ with an ARB attenuates
the hypokalemic and fasting glucose-modifying effects of
HCTZ. Also, there is evidence to suggest that FD combinations
are also associated with better compliance.21
Irbesartan has no active metabolite, and a terminal half-life
of 11–15 h, accounting for its single daily use, potent, angioten-
sin receptor 1 (AT1) receptor antagonist,with high selectivity for
theAT1 receptor subtype. Results of recent clinical studies show
that irbesartan safely and effectively lowers BP within 1 week in
patients with mild-to moderate hypertension.6,24,25
This study was designed with the main objective of evaluat-
ing both; compliance in patients, and persistence of both pa-
tients and physicians to Irbesartan therapy. We looked at the
general acceptance of the Irbesartan therapy among patients
and physicians, and examined the relationship between satis-
faction and compliance as a major factor in determining persis-
tence, and eventually control of BP.
2. Subjects and methods
2.1. Study design
This national, multicenter, prospective product registry con-
ducted in Egypt, in around 220 sites, comprised an initial
screening visit where 6399 patients with essential hypertension,
either newly discovered or uncontrolled on current regimen
were screened for compliance, satisfaction with their current
antihypertensive regimen, and main reasons for dissatisfaction.
Furthermore, the reason for prescribing a speciﬁc antihyper-
tensive drug by physicians was documented. Only patients
for whom physicians decided, to prescribe an Irbesartan-based
regimen (IBR) (3971 patients, 62.05%), were followed up for
four months for their compliance and tolerability to prescribed
regimen. At the End of study (EOS), all participating physi-
cians were asked to ﬁll a two page case report form (CRF)
to point out the basic characteristics of the individual patient
proﬁle, the reason behind the choice of the antihypertensive
regimen, and a questionnaire to assess the extent and reasons
for persistence or non persistence on therapy. BP was docu-
mented at screening visit and at the EOS. Patient and physi-
cian satisfaction with the Irbesartan therapy was also
documented.
Figure 1 Recruitment outline.
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Male or female patients aged > 18 years, with essential hyper-
tension, whether newly discovered or uncontrolled on current
regimen were screened (6399 patients, 100%). Patients eligible
for follow-up (3971 patients, 62.05%)were those whose treating
physicians decided on their own medical judgment to prescribe
an IBR. The main exclusion criteria were; severe hypertension
(systolic blood pressure (SBP) > 180 mmHg, and/or diastolic
blood pressure (DBP) > 110 mmHg)), secondary or malignant
hypertension, pregnant or nursing women, and those of child-
bearing potential, patients on dialysis or recent cardiovascular
(CV) accident within the last 3 months.
2.3. Observations
Data were collected at screening visit and after 4 months dur-
ing the follow-up visit, in the form of a CRF ﬁlled by the par-
ticipating investigators to answer the key study questions.
Collected data included patient’s age, sex, proﬁle (naı¨ve,
uncontrolled on current regimen), duration of hypertension,
satisfaction and compliance with previous regimen. During
the follow up phase, patients were monitored for their BP
using BP monitors at investigators’ sites, heart rate, missed
doses, adverse events (AEs) and actions required; if any. Any
change in therapy (i.e. dose changes, add-on therapy, switch
to other antihypertensive agents, discontinuation) was also re-
corded, together with the reason for the change. At the EOS,
the opinions of both, patients and physicians and their level
of satisfaction with the current regimen were recorded.
3. Statistical analysis and sample size calculation
The targeted population size to be followed up on Irbesartan
based regimen was estimated to be around 2300 patients, based
on the fact that Irbesartan was prescribed to about 4% of
hypertensive patients in Egypt, and assuming a compliance
of 60–70% on Irbesartan as proven in the ICE project.26
Descriptive methods were used for the analysis of the pri-
mary and secondary outcomes, including calculation of appro-
priate measures of the empirical distribution (mean, standard
deviation, median, minimum, maximum, for continuous vari-
ables, and frequencies and percentages for categorical vari-
ables) as well as calculation of descriptive p-Values for group
comparisons. Quantitative data were analyzed for normal dis-
tribution using paired t-test and repeated measures analysis.
Qualitative data were analyzed using Chi square test.
4. Satisfaction and compliance assessment
Recruited patients were followed up for 4 months regarding
their compliance to prescribed regimen, and the reason for
non-compliance was documented together with the average
number of missed doses. The level of satisfaction with current
regimen was also documented at the EOS based on both; pa-
tient’s and physician’s opinions.
4.1. Efﬁcacy assessment
The study, although had no endpoints regarding the efﬁcacy of
the treatment, we elected to analyze the BP values measured atscreening visit and again at the time of BP control (or EOS),
for mean reduction in BP compared to baseline values, and
provide an estimate of the overall efﬁcacy. Changes to antihy-
pertensive regimen were also recorded, indicating the reason
for the change and the add-on or target regimen instituted.
4.2. Safety assessment
Patients were followed up for occurrence of any AE, serious
adverse event (SAE), intensity of such events, and their rela-
tion to Irbesartan treatment. Sequelae, remedies, and outcome,
including discontinuation of therapy, were also recorded.
5. Results
5.1. Recruitment
As represented in Fig. 1, out of 6399 screened patients, Irbesar-
tan regimen was prescribed for a total of 3971 (62.05%) pa-
tients, of whom, 2275 patients (57.29%) representing the
Irbesartan follow-up population were followed up and at-
tended the EOS visit, while 1696 patients (42.70%) were lost
to follow up – IBR drop-out population.
5.1.1. Patient baseline characteristics
As shown in Table 1, the mean age of patients was
52.8 ± 9.59 years. Males represented 57.2%, while females
represented 42.8%. The mean SBP was 158.6 ± 13.58 mmHg
while the mean DBP was 97.67 ± 6.62 mmHg. Treatment na-
ı¨ve (newly discovered hypertension) patients constituted
31.04% of the screened patients, while 68.96% were already
on anti-hypertensive medication at screening with mean treat-
ment duration of 33.28 ± 22.01 months. Patients’ hyperten-
sion history is listed in Table 2.
5.2. Drivers for choice of antihypertensive regimen
ARBs were the most frequently prescribed anti-hypertensive
medications. They were prescribed for 68.9% of the total
screened population, followed by ACE-Is, beta-blockers,
diuretics, and calcium-channel blockers at a prescription rate
of 10.5%, 9.3%, 7.2%, and 4%, respectively.










Naive 1249 (31.5) 1986 (31.04%)
On anti-hypertensive medication 2722 (68.5) 4413 (68.96%)
Duration of last antihypertensive (months)
Mean 29.7 33.28
±SD 18.82 22.01
Table 1 Patients’ baseline characteristics and demographics.
Patients on IBR 3971 (100%) Enrolled population 6399 (100%)
Mean age (±SD) – years 52.84 (9.437) 52.8 (9.587)
Sex
Male 2310 (58.2) 3662 (57.2%)
Female 1661 (41.8) 2737 (42.8%)
Mean SBP (±SD) – mmHg 160.443 (12.664) 158.6 (13.583)
Mean DBP (±SD) – mmHg 98.57 (6.484) 97.67 (6.622)
Heart rate (±SD) – beat/min 82 (9.458) 81 (9.847)
Medical history
Previous signiﬁcant diseases 774 (19.5) 1212 (18.9)
Ongoing diseases 2339 (58.9) 3655 (57.1)
Diabetes mellitus 1586 (39.9) 2476 (38.7)
Dyslipidemia 1158 (29.2) 1747 (27.3)
38 K. Leon et al.Among all treatment groups, three factors were identiﬁed as
the main drivers for antihypertensive drug choice, namely: efﬁ-
cacy (mean = 85.92% of patients), safety (mean = 62.3% of
patients), and cost (mean = 39.64% of patients).
In patients who were on Irbesartan (IBR follow-up pop.,
n= 2275), 240 (10.5%) required a change in therapy at the
end of the study, the reasons for the choice of the newly pre-
scribed medication were efﬁcacy for 88.33%, safety proﬁle
for 60.83% and cost for 15.83% of patients requiring a therapy
modiﬁcation.Figure 2 Satisfaction and compliance of naı¨ve patients. (a) Satisfactio5.3. Satisfaction and compliance
5.3.1. Patient and physician satisfaction with antihypertensive
medications – ‘‘all non-naı¨ve screened patients’’ – n = 4413
As represented in Fig. 2, in the total screened population; pa-
tient and physician input concerning the satisfaction and dis-
satisfaction related to previously prescribed anti-hypertensive
medication, at screening visit, were as follows; out of 4413 pa-
tients on anti-hypertensive therapy, 38.3% of patients were
satisﬁed with their medication. On the contrary, 61.7% were
not satisﬁed. Reasons for dissatisfaction included insufﬁcient
BP control (52.3%) or side effects (24%). According to physi-
cians’ opinion; they were satisﬁed with the antihypertensive
medication for 32.3% of patients, while dissatisﬁed for
67.7% of patients. Reasons for physicians’ dissatisfaction in-
cluded insufﬁcient BP control (59.2%) and side effects
(22.1%).
85.6% of patients were compliant to their antihypertensive
medication at screening visit while 14.4% were non compliant
with an average of 2.75 ± 1.24 missed doses per month.
5.3.2. Patient and physician satisfaction in patients already on
an IBR at screening visit (n = 2722)
Out of 2722 patients who were already on a previous IBR at
screening visit, 27.4% of patients were satisﬁed with their pre-
vious Irbesartan-based medication. On the contrary 72.6%
were dissatisﬁed. Reasons for dissatisfaction includedn/dissatisfaction, (b) reason for dissatisfaction, and (c) compliance.
Figure 3 Satisfaction and compliance of patients already on Irbesartan at screening visit. (a) Satisfaction/dissatisfaction, (b) reason for
dissatisfaction and (c) compliance.
Figure 4 Satisfaction and compliance of patients at the end of study. (a) Satisfaction/dissatisfaction, (b) reason for dissatisfaction and (c)
compliance.
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According to physicians’ opinion; they were satisﬁed with
the previous Irbesartan-based medication for (23.7%) of pa-
tients, while dissatisﬁed for 76.3% of patients. Reasons for
physicians’ dissatisfaction included insufﬁcient BP control
(67.4%) and encountered side effects (25.5%). Patients
(86%) were compliant to their current antihypertensive medi-
cation at screening visit, while 14% were non compliant with
an average of 2.37 ± 1.03 missed doses per month. The data
are demonstrated in Fig. 3.
5.3.3. Patients’ satisfaction with IBR at follow up visit
(n = 2275)
At the follow up visit as shown in Fig. 4, patients showed a sig-
niﬁcant increase in their satisfaction rate where 96.4% of pa-
tients were satisﬁed with their Irbesartan treatment (P
value < 0.001). On the contrary, 3.6% of patients were not
satisﬁed with their Irbesartan treatment. Reasons for dissatis-
faction included, insufﬁcient BP control, high cost or side ef-fects in 1.9%, 1.8% and 0.1% of patients, respectively.
Physicians showed a signiﬁcant increase in their satisfaction
rate to reach 96.3% satisfaction with Irbesartan therapy com-
pared to previous antihypertensive medications (P va-
lue < 0.001), while dissatisfaction was reported for 3.7% of
physicians. Reasons for physicians’ dissatisfaction included
insufﬁcient BP control, side effects and cost of medication
for 3.1%, 0.1% and 0.7% of patients, respectively. Subse-
quently, improvement in both patients’ and physicians’ satis-
faction was reﬂected on the compliance of patients to
Irbesartan based regimen, which was signiﬁcantly improved.
Patients (95.7%) showed compliance to Irbesartan (P
value < 0.001).
5.4. Heart rate and BP changes
At follow up, overall patients on Irbesartan based regimen
showed a signiﬁcant mean reduction of 30.39 ± 1.47 mmHg
in SBP and 16.33 ± 1.45 mmHg in DBP (P value < 0.001).
Figure 5 Baseline vs. End-of-study values.
40 K. Leon et al.Also, heart rate showed insigniﬁcant mean reduction as repre-
sented in Fig. 5.
5.5. Change of therapy
As shown in Fig. 6, out of the 2275 patients who attended the
follow up visit, 240 patients (10.5%) had their therapy changed
including dose changes; 155 patients (6.8%) had an add onFigure 6 Change of therapy.therapy and 85 patients (3.7%) had their therapy replaced.
Reasons for change of therapy included; ineffectiveness, poor
tolerance, and high cost in 140 (6.2%), 61 (2.7%) and 32
(1.4%) patients, respectively.5.6. Safety proﬁle
The safety was analyzed using the data from all patients on
IBR population, n= 3971. Out of 3971 patients, AEs were re-
ported in 137 (3.45%) patients. These AEs were mild to mod-
erate in intensity with probable causal relation to study
medication in 105 (2.85%) patients. All AEs experienced were
not-serious and recovered without any sequelae.
Dizziness was the most common reported AE, being re-
ported by 55 (1.39%) patients. Gastro-Intestinal Tract (GIT)
disturbances were the second most common AEs reported by
47 (1.18%) patients. Headache, musculoskeletal pain and al-
lergy were reported by 27 (0.68%), 6 (0.15%) and 2 (0.05%)
patients respectively.6. Discussion
This study showed that there is a strong relationship between
efﬁcacy, safety and compliance. Patients not controlled on
their antihypertensive regimens are likely to lose conﬁdence
in the effectiveness of their medication, and gradually develop
non compliance, which in turn affects the patient’s overall per-
sistence and willingness to continue receiving their medica-
tions. On the other hand, an effective medication possessing
numerous undesirable side effects, have a similar impact on
compliance. Accordingly, efﬁcacy and safety cannot be sepa-
rated when dealing with patient non compliance.
During the follow up visit, although we expected a great
improvement in patient satisfaction and compliance, the
improvement was beyond our expectations. 96.4% of patients
were satisﬁed with Irbesartan regimen compared to 27.4% at
the beginning of the study (screening visit), and 95.7% of pa-
tients showed improved compliance compared to 86% at
screening visit.
This study demonstrated that the use of an antihypertensive
regimen that is both effective and safe, can positively and sig-
niﬁcantly inﬂuence patient’s satisfaction and compliance. It is
clear that the patients only represent one side of the equation;
physicians also need to have a similar conﬁdence in the medi-
cation, to be willing to prescribe it, and hence, allow the pa-
tient to inherit a similar conﬁdence.
This study showed that the provision of Irbesartan as an
effective and safe antihypertensive agent, promoted patient
compliance, and eventually lead to patients’ persistence on
therapy, which is likely to be reﬂected on their quality of life
(QOL) as well.
In addition, the economical impact of efﬁcient BP control
(achieved through the use of an effective regimen in a compli-
ant patient), especially in developing countries, should not be
overlooked.
Although this study has investigated the relationship be-
tween efﬁcacy, safety, and patient’s compliance, other factors
known to affect compliance still need to be examined, includ-
ing daily frequency of administration, ease of use and patient
awareness. Future studies should consider incorporating a
Observational study on patients’ compliance with Irbesartan in essential hypertension ‘‘I Comply’’ 41wider range of factors to examine the interactions between
these factors and their collective impact on the overall
compliance.
7. Conclusion
Out of the total screened patients, Angiotensin II Receptor
Blockers (including all forms of Irbesartan) were the most pre-
scribed anti-hypertensive medications, being prescribed to
68.9% of the total screened patients. Patients (31.5%) pre-
scribed an Irbesartan-based regimen were naı¨ve, while 68.5%
were already on an antihypertensive regimen. The main drivers
for prescribing antihypertensive drugs were identiﬁed as efﬁ-
cacy, safety proﬁle and cost of the prescribed medication.
Irbesartan based regimen as an antihypertensive agent for
the treatment of essential hypertension showed a signiﬁcant
improvement in the satisfaction rate of both, patients and phy-
sicians, compared to previous medications that was reﬂected
on the compliance of patients, which was signiﬁcantly im-
proved. 95.7% of patients showed compliance on Irbesartan
compared to their previous antihypertensive medications. Per-
sistence rate for Irbesartan based regimen during the study
duration was 89.5%. Physicians (96.3%) were satisﬁed with
the Irbesartan regimen, at the follow up visit (compared to
23.7% at screening visit).
Patients on Irbesartan based regimen showed a signiﬁcant
mean reduction of 30.39 ± 1.47 mmHg in SBP and
16.33 ± 1.45 mmHg in DBP.Acknowledgments
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